Cogent Biosciences

ACTR087 is a monoclonal antibody (mAb) in development by Cogent Biosciences for lymphoma. The program, identified by internal code UT-201501, completed Phase 1 clinical evaluation as of March 31, 2020. The specific mechanism of action and molecular target have not been disclosed. ACTR087 represents Cogent's early-stage immunotherapy approach to lymphoid malignancies, a disease area with multiple approved and investigational therapies. The Phase 1 trial (NCT02776813) has concluded, but detailed efficacy and safety data, as well as plans for advancement to Phase 2, have not been publicly reported. No regulatory filings, approvals, or commercial milestones have been announced. The competitive landscape for lymphoma includes established small-molecule and antibody-based therapies from major pharmaceutical sponsors, as well as several agents in Phase 3 development. Future development trajectory and commercial strategy for ACTR087 remain undisclosed.

Lymphoma represents a significant unmet medical need despite the availability of multiple approved therapies. The disease encompasses diverse histological subtypes with varying prognoses and treatment responses, creating opportunities for novel immunotherapeutic approaches. ACTR087's monoclonal antibody platform addresses the lymphoma market, which continues to expand with new mechanism classes and combination strategies. The competitive environment includes both established standards of care (Brentuximab vedotin, ibrutinib, temsirolimus) and emerging Phase 3 candidates, indicating sustained investment in this indication. Cogent Biosciences' entry into lymphoma with a mAb suggests confidence in antibody-based targeting strategies for hematologic malignancies. The patient population for lymphoma spans multiple subtypes and treatment lines, creating diverse commercial opportunities. However, ACTR087's current Phase 1 completion status and lack of disclosed efficacy data limit near-term commercial significance. The program's advancement will depend on Phase 1 safety and preliminary activity signals, which have not been publicly reported. Successful differentiation from approved therapies and Phase 3 competitors will be critical for future development and market positioning.

Drug Class: Monoclonal antibody (mAb)

Modality: Protein therapeutic; antibody-based immunotherapy

Mechanism of Action: Not yet disclosed

Molecular Target: Not yet disclosed

Route of Administration: Not yet disclosed

Indication: Lymphoma

Related Therapies: Brentuximab vedotin (Takeda; antibody-drug conjugate), ONTAK/denileukin difitox (Ligand Pharmaceuticals; fusion protein), ibrutinib (AbbVie; Bruton tyrosine kinase inhibitor), temsirolimus (Pfizer; mTOR inhibitor), etoposide (topoisomerase II inhibitor)

Patent Status: Not yet disclosed

First Approval: Not applicable; program in Phase 1

FDA Status: Not yet disclosed. ACTR087 has not filed for FDA approval and remains in Phase 1 development.

EMA Status: Not yet disclosed.

PMDA (Japan) Status: Not yet disclosed.

NMPA (China) Status: Not yet disclosed.

No regulatory interactions, breakthrough designations, orphan drug designations, or expedited review pathways have been publicly announced for ACTR087. The program's regulatory strategy and intended jurisdictions for initial filing remain undisclosed.

Development Stage: ACTR087 remains in early clinical development with Phase 1 completion as of March 2020. The absence of disclosed Phase 1 data or advancement announcements suggests either ongoing data analysis or deprioritization of the program.

Competitive Positioning: As a monoclonal antibody for lymphoma, ACTR087 enters a crowded market with established antibody-based therapies (Brentuximab vedotin, ONTAK) and multiple small-molecule alternatives. Differentiation will depend on the undisclosed target and mechanism, as well as Phase 1 safety and activity signals.

Strategic Implications: Cogent Biosciences' investment in lymphoma immunotherapy aligns with industry focus on hematologic malignancies. However, the lack of public updates since 2020 raises questions about program momentum and commercial prioritization.

Future Catalysts: Publication of Phase 1 data, announcement of Phase 2 initiation or discontinuation, disclosure of mechanism and target, and any regulatory interactions would provide clarity on ACTR087's development trajectory.

Commercial Outlook: Near-term commercial significance is limited. Success will require demonstration of superior efficacy, safety, or convenience versus approved and Phase 3 competitors, coupled with advancement through Phase 2 and Phase 3 development.